deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05941897

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy (LOTOS)

A Phase II, Open-label, Multicentre, Non-comparative, Single-arm Local Study of Ceralasertib Plus Durvalumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Sponsor: AstraZeneca

Conditions Advanced or Metastatic NSCLC
Interventions Ceralasertib Durvalumab
Updated 15 times since 2023 Last updated: Mar 4, 2026 Started: Jun 21, 2023 Primary completion: Jul 29, 2024 Completion: Jan 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced or Metastatic NSCLC, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 15 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshotActive Not Recruiting~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshotActive Not Recruiting~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshotActive Not Recruiting~Mar 2025 – ~Jun 2025 · 3 months · monthly snapshotActive Not Recruiting~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshotActive Not Recruiting~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Mar 2026 · 5 months · monthly snapshotActive Not Recruiting~Mar 2026 – present · 6 months · monthly snapshotActive Not Recruiting

Change History

15 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Oct 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Dec 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jan 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  7. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  8. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  9. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  10. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations